Antibody composition and application thereof to detection of acute B lymphocytic leukemia

Abstract

The invention provides an antibody composition and application thereof to detection of acute B lymphocytic leukemia. The antibody composition comprises four groups of antibodies; the first group of antibodies includes a CD38 antibody, an anti-CD10 antibody, an anti-CD34 antibody, an anti-CD19 antibody, an anti-CD20 antibody and an anti-CD45 antibody; the second group of antibodies includes an anti-cytoplasm CD79a antibody; the third group of antibodies includes an anti-CD81 antibody, an anti-CD34 antibody, an anti-CD10 antibody and an anti-CD45 antibody; and the fourth group of antibodies includes an anti-TdT antibody and an anti-cytoplasm CD79a antibody. The antibody composition disclosed by the invention can be applied to detecting acute B lymphocytic leukemia and / or minimal residual disease by flow cytometry, and can be used for effectively selecting B cells in a gating manner, including B cells of CD19- and B cells of CD19+, and the B cells cover the most complete immature B cell population and even B cell population, so that the missed diagnosis probability is reduced.

Description

Technical field [0001] The present invention relates to an antibody composition and its application in leukemia detecting acute B lymphocytes, belonging to the field of blood disease testing. Background technique [0002] In recent years, the incidence of leukemia / lymphoma has increased significantly, and has become one of the important diseases affecting human health. Acukaemia, ALL is 15% of all leukemia, accounting for about 30% -40 of acute leukemia. %, 80-85% of B Cell type (B-All). In the United States, the incidence of ALL is 1.38 / 100,000 per year. There are about 5930 cases of new cases per year, and 1,500 deaths. Domestic research shows that the incidence of male ALL in Shanghai from 2008 to 2012 is 0.86 / 100,000, and the incidence of female ALL is 0.76 / 100,000, and the incidence rate is 0.69 / 100,000 from 1986 to 1988. [0003] With the continuous emergence of new therapies such as targeted therapy, leukemia, lymphoma has a cure hope, and the current treatment m...

AI Technical Summary

Problems solved by technology

However, the correct selection of antibody composition is the key to achieve the above goals. For example, the most conventional analysis scheme is the membrane pan-B cell marker CD19 supplemented with SSC or CD45 (CD19 / SSC or CD45 / CD19 dual parameters) for gating However, for patients after CD19-CAR-T cell infusion treatment, using CD19 to set up a gate is no longer applicable, because after treatment, some normal or abnormal B cell surface CD19 antigens have shown loss of expression or weakened, so it is urgent to find a new effective solution that can set the gate to select the target B cells

[0006] In order to solve this problem, researchers have done research explorations, including the study of Washington University using CD22 combined with CD24+ / CD66c- gate B cells to detect MRD after CAR-T cell infusion therapy, but it still has the following defects : 1. The expression rate of CD24 in B-ALL is 80.6%. Especially in ALL-B with MLL gene rearrangement, the expression of CD24 is prone to decrease or loss, which affects the gating efficiency of B cells. 2. The expression rate of CD22 in basophilic It is expressed or weakly expressed in granulocytes, plasmacytoid dendritic cells, and mast cells, so the specificity is not good, and the CD22 antigen gradually increases in intensity as the cells mature during the maturation process of normal B cells. In B-ALL, the expression of CD22 on naive B cells is reduced, which affects the sensitivity of CD22 gating to select B cells

3. Patients not suitable for CD22-CAR-T cell or CD19-CD22-CAR-T dual-target cell infusion therapy

Images